Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a ...


1.
  • Haroon M
  • Gallagher P
  • FitzGerald O

Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis.

Ann Rheum Dis. 2015; 74: 1045-10502.
  • Ritchlin CT
  • Colbert R.A
  • Gladman DD

Psoriatic arthritis.

N Engl J Med. 2017; 376: 2095-20963.
  • Coates LC
  • Kavanaugh A
  • Mease PJ
  • et al.

Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis.

Arthritis Rheumatol. 2016; 68: 1060-10714.
  • Gossec L
  • Baraliakos X
  • Kerschbaumer A
  • et al.

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.

Ann Rheum Dis. 2020; 79: 700-7125.
  • Singh YES
  • Guyatt G
  • Ogdie A
  • et al.

Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis.

Arthritis Rheumatol. 2019; 71: 5-326.
  • Smolen JS
  • Schols M
  • Brown J
  • et al.

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.

Ann Rheum Dis. 2018; 77: 3-177.
  • Orbai AM
  • de Wit M
  • Mease P
  • et al.

International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials.

Ann Rheum Dis. 2017; 76: 673-6808th.
  • Coates LC
  • fringes j
  • Helliwell PS

Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment.

Ann Rheum Dis. 2010; 69: 48-539.
  • Coates LC
  • Navarro-Coy N
  • Brown Sr
  • et al.

The TICOPA protocol (tight control of psoriatic arthritis): a randomized controlled trial to compare intensive management versus standard care in early psoriatic arthritis.

BMC Musculoskeletal Disord. 2013; 14: 10110
  • Wells GA
  • Boers M
  • Shea B
  • et al.

Minimal disease activity for rheumatoid arthritis: a preliminary definition.

J Rheumatol. 2005; 32: 2016-202411.
  • Lie E
  • van der Heijde D
  • Uhlig T
  • et al.

Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.

Ann Rheum Dis. 2010; 69: 671-67612.
  • Nikiphorou E
  • Negoescu A
  • Fitzpatrick JD
  • et al.

Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort.

Clin Rheumatol. 2014; 33: 609-61413.
  • Kingsley GH
  • Kowalczyk A
  • Taylor H
  • et al.

A randomized placebo-controlled trial of methotrexate in psoriatic arthritis.

Rheumatology (Oxford). 2012; 51: 1368-137714
  • Baranauskaite A
  • Raffayova H
  • Kungurov NV
  • et al.

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.

Ann Rheum Dis. 2012; 71: 541-54815

Methotrexate efficacy in the tight control in psoriatic arthritis study.

J Rheumatol. 2016; 43: 356-36116
  • Ash Z
  • Gaujoux-Viala C
  • Gossec L
  • et al.

A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis.

Ann Rheum Dis. 2012; 71: 319-32617
  • Acosta Felquer ML
  • Coates LC
  • Soriano ER
  • et al.

Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review.

J Rheumatol. 2014; 41: 2277-228518
  • Soriano ER
  • Acosta-Felquer ML
  • Luong P
  • Caplan L

Pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biologic and non-biologic DMARDs.

Best Practice Res Clin Rheumatol. 2014; 28: 793-80619
  • Gossec L
  • Smolen JS
  • Ramiro S
  • et al.

European league against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.

Ann Rheum Dis. 2016; 75: 499-51020
  • Kavanaugh A
  • Mease PJ
  • Gomez-Reino JJ
  • et al.

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Ann Rheum Dis. 2014; 73: 1020-102621
  • McInnes IB
  • Kavanaugh A
  • Gottlieb AB
  • et al.

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

lancet 2013; 382: 780-78922
  • Ritchlin C
  • Rahman P
  • Kavanaugh A
  • et al.

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumor necrosis factor therapy: 6-month and 1-year results of the phase 3 , multicentre, double-blind, placebo-controlled, randomized PSUMMIT 2 trial.

Ann Rheum Dis. 2014; 73: 990-99923
  • Behrens F
  • Koehm M
  • Arndt U
  • et al.

Does concomitant methotrexate with adalimumab influence treatment outcomes in patients with psoriatic arthritis? Data from a large observational study.

J Rheumatol. 2016; 43: 632-63924
  • Mease PJ
  • Gladman DD
  • Collier DH
  • et al.

Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial.

Arthritis Rheumatol. 2019; 71: 1112-112425
  • Mease PJ
  • Gladman DD
  • Samad AS
  • et al.

Design and rationale of the study of etanercept and methotrexate in combination or as monotherapy in subjects with psoriatic arthritis (SEAM-PsA).

RMD Open. 2018; 4e00060626

Psoriasis: Which therapy for which patient: psoriasis comorbidities and preferred systemic agents.

J Am Acad Dermatol. 2019; 80: 27-4027

Psoriasis: which therapy for which patient: focus on special populations and chronic infections.

J Am Acad Dermatol. 2019; 80: 43-5328
  • McInnes IB
  • Behrens F
  • Mease PJ
  • et al.

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.

lancet 2020; 395: 1496-150529
  • Mease PJ
  • Smolen JS
  • Behrens F
  • et al.

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.

Ann Rheum Dis. 2020; 79: 123-13130
  • Taylor W
  • Gladman D
  • Helliwell P
  • Marchesoni A
  • Mease P
  • Mielants H

Classification criteria for psoriatic arthritis: development of new criteria from a large international study.

arthritis rheumatism. 2006; 54: 2665-267331
  • Smolen JS
  • Landewé RBM
  • Bijlsma JWJ
  • et al.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.

Ann Rheum Dis. 2020; 79: 685-69932
  • Behrens F
  • Koehm M
  • Schwaneck EC
  • et al.

Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis.

Scand J Rheumatol. 2019; 48: 375-38233
  • Ryan C
  • Sobell JM
  • Leonardi CL
  • et al.

Safety of adalimumab dosed every week and every other week: focus on patients with hidradenitis suppurativa or psoriasis.

Am J Clin Dermatol. 2018; 19: 437-44734
  • ship MH
  • Jaffe JS
  • Friendly B

Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration.

Ann Rheum Dis. 2014; 73: 1549-1551
continue reading

https://dailytechnonewsllc.com/comparison-between-adalimumab-introduction-and-methotrexate-dose-escalation-in-patients-with-inadequately-controlled-psoriatic-arthritis-control-a-randomised-open-label-two-part-phase-4-study/

Comments

Post a Comment

Popular posts from this blog

China’s new space station opens for business in an increasingly competitive era of space activity

The International Space Station is no longer the only place where humans can live in orbit. On Nov. 29, 2022, the Shenzhou 15 mission launched from China's Gobi Desert carrying three taikonauts – the Chinese word for astronauts. Six hours later, they reached their destination, China's recently completed space station, called Tiangong, which means "heavenly palace" in Mandarin. The three taikonauts replaced the existing crew that helped wrap up construction. With this successful mission, China has become just the third nation to operate a permanent space station. China's space station is an achievement that solidifies the country's position alongside the US and Russia as one of the world's top three space powers. As scholars of space law and space policy who led the Indiana University Ostrom Workshop's Space Governance Program, we have been following the development of the Chinese space station with interest. Unlike the collaborative, US-led Inte
Read more

North Uist spaceport scheme could 'review' role of Russia-linked firm

Image
Plans to build a rocket-launching spaceport in the Outer Hebrides could be dealt a blow over links to Russia, we can reveal. Western Isles Council has signaled it may need to order a “review” of its partnership with consultancy firm Commercial Space Technologies (CST) Ltd, depending on future government advice. The firm is registered in the UK but has long-standing connections with Russia. Scottish ministers urged businesses on Thursday to cut their ties to Russia amid international outrage at Vladimir Putin's decision to invade Ukraine. CST said it had sought advice from the UK Government's department of international trade. The company is involved in a consortium which is driving the Spaceport 1 project at North Uist. North Uist It is working alongside the local authority, also known as Comhairle nan Eilean Siar, development agency Highlands and Islands Enterprise (HIE), and defense firm QinetiQ. The original plans attracted a flood of objects, but h
Read more

How Iran is accessing the social media accounts of protesters to incriminate them, experts say

Image
CNN — In between being blindfolded, locked in solitary confinement, and interrogated in a wheelchair while she was on a hunger strike following her late September arrest, Negin says she had a realization: Iranian officials were using her private Telegram chats, phone logs and text messages to incriminate her. “They told me 'Do you think you can get out of here alive? We will execute you. Your sentence is death penalty. We have evidence, we are aware of everything,'” said Negin, whose name CNN changed at her request, for her safety. Negin, who says she has been accused by Iranian authorities of running an anti-regime activist group on Telegram (an allegation she denies), said she has “some friends” who were political prisoners. “They put in front of me transcribed printouts of my phone conversations with those friends,” she said, and “questioned me on what my relationship with tho
Read more